Future pharmas may be increasingly specialized; Western vanity projected to drive cosmeceuticals;

> Expect pharma manufacturers may become increasingly specialized as they adopt strategies based on particular diseases related to specific systems in the human body or targeted populations. Analysis

> An aging population bent on maintaining its youth is expected to push U.S. demand for cosmeceuticals to 5.8% a year to reach $8.5 billion in 2015, projects Freedonia Group. Report

> The biggest challenge facing India in the food and drug industries is supply chain infrastructure, which "really needs to be overhauled for foreign players, contract manufacturing and cold-chain storage." Article

> Drug-delivery specialist OctoPlus wants you, if you're a specialty manufacturer of generics interested in controlled-release technology. Story

> BioAlliance Pharma will produce clinical batches of the orphan-designated Livatag (doxorubicin Transdrug), an injectable cytotoxin in nanoparticle form for a Phase III trial in liver cancer. Story

> Cadila Pharmaceuticals in Ethiopia anticipates international GMP certification from the Pharmaceutical Inspection Cooperation Scheme. Item

> Baxter in Europe has been named a "Great Place to Work" by the GPTW Institute. News

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.